drug · small molecule

DYANAVEL XR

updated 2mo ago

by $TRAW Traws Pharma, Inc.🔗 ChEMBL

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for attention deficit hyperactivity disorder and 3 investigational indications.

targets

Sodium-dependent dopamine transporterSodium-dependent noradrenaline transporter

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

DYANAVEL XR

trade names

Adzenys er, Adzenys xr-odt, Dyanavel xr, Mydayis (mixed salts of a single entity)

generic

AMPHETAMINE

MOA

12.1 Mechanism of Action Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in ADHD is not known.

indication

1 INDICATIONS AND USAGE DYANAVEL XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older [see Clinical Studies (14) ]. Limitations of Use The use of DYANAVEL XR is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions (5.5) , Use in Specific Populations (8.4) ]. DYANAVEL XR is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older ( 1 ) Limitations of Use The use of DYANAVEL XR is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage ( 5.5 , 8.4 ).

DYANAVEL XR

targets

all catalysts(0)

News(0)

Report a data issue

comments(0)

🐶 often sniffed alongside

Trials studying DYANAVEL XR